---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056866"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:33:19.070601+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q1 2024 net loss $8.6M, cash $13.0M; first patient dosed in INB-400 Phase 2

## Summary
- Q1 net loss $8.6M ($0.20/sh) vs $7.5M ($0.30/sh) in Q1 2023; R&D $4.9M, G&A $3.7M.
- Cash $13.0M at March 31, 2024, down from $21.3M at December 31, 2023.
- First patient dosed in Phase 2 autologous arm of INB-400 for newly diagnosed GBM.
- Potential IND submission for INB-100 Phase 2 registrational trial in 2024 in AML/MDS.
- Preclinical nsCAR data at AACR 2024 targeting CD33/CD123 for AML while sparing healthy cells.

## SEC filing metadata
- accession: 0000950170-24-056866
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/0000950170-24-056866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/inab-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056866
- JSON: https://secwatch.observer/filing/0000950170-24-056866.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.